Wegovy: FDA Reduces Heart Risks

Wegovy

Wegovy is a weight-loss drug for people suffering from obesity and has now been recognized for its potential cardiovascular health benefits. The FDA (Food & Drug Administration) approved its use to reduce the future risk of heart strokes, especially in adults who are dealing with cardiovascular diseases, along with obesity or being overweight. However, as advised by the FDA, people need to manage their calorie diet and include physical activity too when taking these injections. This post explores why the FDA approved Wegovy for reduced heart risks. From clinical results to potential side effects, we will discuss everything in this guest post, so that you have all the information when you buy Wegovy from Canada.

What Were the Results of the Wegovy Study for Heart Risk?

The FDA approval of semaglutide as the weight loss drug based on Novo Nordisk’s SELECT trial or Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity. In the trial (as mentioned in the Novo Nordisks’ press release), researchers included 17,600 adults aged 45 and over with heart disease. These patients received either a weekly 2.4-milligram dose of semaglutide (a drug used in Wegovy) or a placebo. 

All of the study participants were either overweight or obese but were not patients with diabetes. After about 3 years of monitoring, there were cardiovascular events such as heart stroke and attacks, in which 569 participants belonged to the semaglutide group, and 701 were from the placebo. This indicates a 20% lowered heart risk in people who used Wegovy injection as a medication. 

These results hold more value as conventional weight-loss drugs such as phentermine or orlistat have not shown protective effects against heart conditions.

The Connection Between Semaglutide and Heart Health

During the SELECT trial, participants who took semaglutide experienced improved heart health, including reduced inflammation, lower blood pressure, and decreased levels of bad cholesterol. These factors are all closely linked to the risk of developing cardiovascular diseases. Additionally, clinical trials such as the SUSTAIN 6 study have specifically investigated the cardiovascular outcomes associated with semaglutide. These studies showed an impressive reduction in the risk of major heart-related issues like strokes and heart attacks among users compared to those on a placebo. This research has strengthened the connection between semaglutide and better heart health, showing that it’s useful not just for treating diabetes but also for preventing serious heart conditions.

How Many People Received Wegovy’s Heart Benefits?

A follow-up study conducted by Yale estimates that approximately 6.6 million Americans who have obesity and cardiovascular issues, excluding diabetes, benefited from using semaglutide injection. According to a Yale study which was published in the medical journal of Cardiovascular Quality and Outcome, the scientists compared national databases, looking for people with characteristics similar to those in the SELECT trial. 

Then, they used this group to guess how many people in the whole country might benefit from this drug. As a result, the study came to the conclusion that the availability and accessibility of the medication could lead to a shift in how heart disease is addressed. 

What Impact Will Recent Approval of Wegovy Have?

The recent FDA approval of the weight loss drug semaglutide, associated with reduced heart risk, will have several impacts:

  • Impact on Patients: Now, individuals who didn’t qualify based only on weight criteria but are both overweight and suffer from heart disease can receive this medication. Additionally, the FDA approval for reducing the risk of cardiovascular disease may lead insurers to cover the medication for those at risk of heart-related problems, potentially increasing access for consumers.
  • Impact on Healthcare Providers: As noted by the FDA, semaglutide, the drug used in Wegovy injection, has the ability to address two leading causes of preventable deaths—obesity and heart disease. As a result, medical professionals gain an effective tool for treating patients with the above-mentioned disease more comprehensively.

Potential Side Effects & How to Manage Them

While approved by the FDA to prevent heart risks, Wegovy can have some side effects. We will provide you with a list of these side effects, along with ways you can manage them for effective weight management.

Stomach Problems 

Side effects such as nausea and diarrhea are common with GLP-1 agonist drugs like semaglutide. These problems are usually mild and temporary and often go away in a few weeks. People are more likely to notice these stomach issues at the beginning of the treatment when the drug dose increases. 

How to Manage?

  • Take small meals
  • Consume low-fat food (crackers, toast, or rice)
  • Do not lie down immediately after eating.

Contact your healthcare provider if the issue doesn’t go away.

Low Blood Sugar

Also referred to as hypoglycemia, semaglutide injection treatment can leave adults and adolescents with low blood sugar. It is a serious but uncommon side effect that might increase the medication in combination with other type 2 diabetes drugs. 

How to Manage?

If you notice signs of low blood glucose, such as dizziness, tiredness, anxiety, etc., ask your doctor for expert opinions. They might change your dose to suit your body’s needs. 

Gallbladder Problems

Wegovy results in rapid weight loss, leading your gallbladders to face problems like the development of gallstones or inflammation, which might need surgeries. Although gallbladder complications are less frequent than general stomach side effects from the drug, they can be more severe.

How to Manage?

If you have been feeling:

  • A pain in the upper right area of your abdomen
  • Yellowing if your skin or eyes
  • Dark-coloured urine

Consult with your healthcare professionals right away to be evaluated for any possible gallbladder inflammation or stones. Besides, it is essential to note that any unauthentic or low-quality drug can also be a reason for gallstones. So, make sure that you always buy your semaglutide injections from trusted sources or order drugs from Canada

Conclusion

The FDA’s approval for Novo Nordisk’s semaglutide to reduce cardiovascular-related death has opened up new possibilities for patient care. This recent approval targets patients dealing with obesity or overweight conditions, along with heart diseases. A clinical trial found that over five years of Wegovy injection reduced heart risk by 20% than people who received an inactive placebo. 

Besides the positive results among patients using the mentioned weight loss drug, these injectables provide healthcare facilities with an effective tool for treating patients with obesity and CVDs. While the medication has proved its effectiveness, it is important for people to be aware of the common side effects of semaglutide, which are already mentioned in the blog.

Read more related blogs:

Mental Health Awareness Community

Best Foods To Improve Brain Health